Literature DB >> 12163004

Control of von Willebrand factor multimer size and implications for disease.

John Pimanda1, Philip Hogg.   

Abstract

Plasma von Willebrand factor (vWF) is a multimeric protein that mediates adhesion of platelets to sites of vascular injury, however only the very large vWF multimers are haemostatically competent. Plasma vWF derives predominantly from the vascular endothelium and is of a smaller average multimer size to that found in the sub-endothelial matrix. The existence of plasma factors that control the size of vWF multimers and account for this difference has long been suspected. vWF cleaving protease (vWFCP), a metalloproteinase that regulates vWF multimer size by proteolytic cleavage, and thrombospondin-1 (TSP-1), a trimeric glycoprotein that uncouples multimers by reducing the disulfide-bonds which link individual subunits, are two such factors that have recently been identified. The large and ultra large vWF multimers play a central role in arterial thrombosis and agents that regulate their size hold promise as novel anti-thrombotic drugs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163004     DOI: 10.1016/s0268-960x(02)00017-6

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  4 in total

1.  Annexin A2 mediates secretion of collagen VI, pulmonary elasticity and apoptosis of bronchial epithelial cells.

Authors:  Maryann Dassah; Dena Almeida; Rebecca Hahn; Paolo Bonaldo; Stefan Worgall; Katherine A Hajjar
Journal:  J Cell Sci       Date:  2013-12-19       Impact factor: 5.285

2.  Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population.

Authors:  Peter Kamstrup; Jannie Marie Bülow Sand; Charlotte Suppli Ulrik; Julie Janner; Christian Philip Rønn; Sarah Rank Rønnow; Diana Julie Leeming; Sidse Graff Jensen; Torgny Wilcke; Alexander G Mathioudakis; Marc Miravitlles; Therese Lapperre; Elisabeth Bendstrup; Ruth Frikke-Schmidt; Daniel D Murray; Theis Itenov; Apostolos Bossios; Susanne Dam Nielsen; Jørgen Vestbo; Tor Biering-Sørensen; Morten Karsdal; Jens-Ulrik Jensen; Pradeesh Sivapalan
Journal:  Biomedicines       Date:  2022-08-19

3.  Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study).

Authors:  Toshko J Lissitchkov; Evgeny Buevich; Kazimierz Kuliczkowski; Oleksandra Stasyshyn; Monica Hermida Cerqueira; Anna Klukowska; Christine Joch; Wilfried Seifert
Journal:  Blood Coagul Fibrinolysis       Date:  2017-03       Impact factor: 1.276

4.  Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk.

Authors:  Lasse L Langholm; Sarah Rank Rønnow; Jannie M B Sand; Diana Julie Leeming; Ruth Tal-Singer; Bruce E Miller; Jørgen Vestbo; Morten A Karsdal; Tina Manon-Jensen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-03-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.